PET Imaging of Subjects Using 124I-PU-AD

Samus Therapeutics

Status and phase: Terminated; Early Phase 1

Conditions: Alzheimer Disease; Lymphoma; Myeloma; Solid Malignancy

Treatments: Device: PET Scan; Drug: PU-AD; Other: Blood Draws

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03371420

PU-AD-00-001

Details and patient eligibility

About

This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent 124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or myeloma) and/or Alzheimer's disease.

Full description

This first in-human trial of the positron-emitting agent 124I-PU-AD is an open-label pilot (microdose) study. Up to 10 evaluable subjects who have active disease will be enrolled to evaluate the PK, metabolism, biodistribution, and radiation dosimetry of 124I-PU-AD.

Following a 28-day screening period, eligible subjects will return to the clinic on Day 1. A single dose of 124I-PU-AD will be administered by intravenous (IV) injection to subjects.

After 124I-PU-AD tracer injection, PET scans will be performed at 4 time points. At each time-point, an axial body image is acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. Serial blood samples will also be obtained at multiple time points.

Subjects will be evaluated to ensure that there are no clinically significant ongoing AEs prior to discharge.

Enrollment: 5 patients

Sex: All

Ages: 21 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subjects with a diagnosis of cancer and/or Alzheimer's Disease, meeting trial eligibility criteria as specified below for either disease:

   Cancer:

   1. Subjects with eligible histologic types of cancer. Eligible histologic types of cancer include solid malignancy, myeloma, and lymphoma.
   2. Cancer histology confirmed by pathology.
   3. Cancerous disease is radiologically-measurable or evaluable as defined by published tumor response criteria (including but not limited to RECIST 1.1).

   Alzheimer's:

   1. Established diagnosis of mild-moderate Alzheimer's disease based upon neurological and neuropsychological evaluation following the National Institute on Aging - Alzheimer's disease Association criteria that recently revisited the NINCDS-ADRDA criteria.
   2. Documentation of diagnosis of mild-moderate Alzheimer's disease, as above, by board-certified neurologist.

2. Subjects who have both cancer and Alzheimer's Disease, subjects are considered eligible if they meet all eligibility requirements for either Alzheimer's Disease or cancer patients, as specified above.

Exclusion criteria

1. Subject has unacceptable pre-study organ function during screening defined as:

   1. Bilirubin > 1.5 x institutional upper limit of normal (ULN)
   2. AST/ALT >2.5 x ULN
   3. Albumin < 2 g/dl
   4. GGT > 2.5 x ULN (IF Alkaline phosphatase > 2.5 x ULN)
   5. Creatinine >1.5 x ULN or creatinine clearance < 60 mL/min.

2. Subject has history of acute major illness (i.e., unstable cardiovascular condition.)

3. Subject has concurrent participation in any interventional studies within 30 days of first dose of study drug.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

124I-PU-AD

Experimental group

Description:

A single dose of 124I-PU-AD will be administered by intravenous (IV) injection

Treatment:

Other: Blood Draws

Device: PET Scan

Drug: PU-AD